Search

Your search keyword '"Crescenzo, Rocco J."' showing total 11 results
Start Over Author "Crescenzo, Rocco J." Journal blood
11 results on '"Crescenzo, Rocco J."'

2. Impact of Diarrhea on Health-Related Quality of Life: Analysis of the Phase 3 BFORE Trial of Bosutinib Vs Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Author

Brümmendorf, Tim H, primary, Mamolo, Carla M., additional, Reisman, Arlene, additional, Bushmakin, Andrew G, additional, Cappelleri, Joseph C, additional, Crescenzo, Rocco J., additional, DeAnnuntis, Liza, additional, Viquiera, Andrea, additional, and Cortes, Jorge E., additional

Published
2018
Full Text
View/download PDF

3. Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Author

Gambacorti-Passerini, Carlo, primary, Deininger, Michael W., additional, Mauro, Michael J., additional, Chuah, Charles, additional, Kim, Dong-Wook, additional, Dyagil, Iryna, additional, Glushko, Natalia, additional, Milojkovic, Dragana, additional, le Coutre, Philipp D., additional, García Gutiérrez, Valentín, additional, Crescenzo, Rocco J., additional, Leip, Eric, additional, Bardy-Bouxin, Nathalie, additional, Hochhaus, Andrea, additional, Brümmendorf, Timothy H., additional, and Cortes, Jorge E., additional

Published
2017
Full Text
View/download PDF

4. Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Author

Kota, Vamsi, primary, Brümmendorf, Tim H., additional, Gambacorti-Passerini, Carlo, additional, Cortes, Jorge E., additional, Lipton, Jeffrey H., additional, Kantarjian, Hagop M., additional, Kim, Dong-Wook, additional, An, Fiona, additional, Leip, Eric, additional, Crescenzo, Rocco J., additional, Woloj, Mabel, additional, Shapiro, Mark, additional, and Khoury, H. Jean, additional

Published
2016
Full Text
View/download PDF

6. Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Author

Xu, Linlin, Shadman, Mazyar, Flinn, Ian W., Levy, Moshe, Porter, Ryan, Burke, John M., Zafar, Syed F., Cultrera, Jennifer L., Misleh, Jamal, Kingsley, Edwin C., Yimer, Habte A., Freeman, Benjamin B., Chaudhry, Arvind, Tumula, Praveen K., Gandhi, Mitul, Crescenzo, Rocco J., By, Kunthel, Cohen, Aileen Cleary, Idoine, Adam, Manda, Sudhir, and Sharman, Jeff P.

Abstract

Introduction:Bruton tyrosine kinase inhibitors (BTKi) have shown remarkable utility in the treatment of B-cell malignancies; yet some patients have experienced toxicities to the BTKis, ibrutinib and acalabrutinib, which lead to dose reduction or treatment discontinuation. Zanubrutinib is a potent and selective next-generation BTKi. BGB-3111-215 (NCT04116437) is an ongoing, phase 2 study of the safety and efficacy of zanubrutinib monotherapy in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) who discontinued ibrutinib, acalabrutinib, or acalabrutinib and ibrutinib because of intolerance.

Published
2023
Full Text
View/download PDF

7. Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Author

Quach, Hang, Sborov, Doug, Kazandjian, Dickran, Spencer, Andrew, Low, Michael, Bal, Susan, Callander, Natalie S., Cheng, Huan, Patel, Sheel, Crescenzo, Rocco J., Agarwal, Amit, and Dhakal, Binod

Abstract

Background:B-cell lymphoma-2 (BCL2) family proteins represent attractive therapeutic targets as they play an important role in MM cell survival. In patients with relapsed/refractory (R/R) MM harboring t(11;14) for whom multiple prior lines of therapy failed, single-agent venetoclax, a first generation BCL2 inhibitor, demonstrated antimyeloma activity (Kumar S, et al. Blood.2017). Dexamethasone, a long-standing mainstay of treatment for MM, increases the expression of both BCL2 and Bim. This results in a greater dependency on BCL2 for tumor survival, ultimately increasing the sensitivity to a BCL2 inhibitor.

Published
2023
Full Text
View/download PDF

8. Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

Author

Mauro, Michael J., Gambacorti-Passerini, Carlo, Deininger, Michael W., Chuah, Charles, Kim, Dong-Wook, Dyagil, Iryna, Glushko, Natalia, Milojkovic, Dragana, le Coutre, Philipp D., García Gutiérrez, Valentín, Reilly, Laurence, Jeynes-Ellis, Allison, Crescenzo, Rocco J., Uehara, Roberto, Leip, Eric, DeAnnuntis, Liza, Bardy-Bouxin, Nathalie, Hochhaus, Andreas, Brümmendorf, Timothy H., and Cortes, Jorge E.

Published
2017
Full Text
View/download PDF

9. Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level

Author

Hochhaus, Andreas, Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Iryna, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp D., García Gutiérrez, Valentín, Reilly, Laurence, Jeynes-Ellis, Allison, Crescenzo, Rocco J., Leip, Eric, Bardy-Bouxin, Nathalie, Brümmendorf, Timothy H., and Cortes, Jorge E.

Published
2017
Full Text
View/download PDF

10. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

Author

Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Iryna, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp D., García Gutiérrez, Valentín, Reilly, Laurence, Jeynes-Ellis, Allison, Crescenzo, Rocco J., Mamolo, Carla, Reisman, Arlene, Bardy-Bouxin, Nathalie, Hochhaus, Andrea, and Brümmendorf, Timothy H.

Abstract

Introduction:Since many patients with chronic phase chronic myeloid leukemia (CP CML) achieve long-term survival, health-related quality of life (HR-QOL) as assessed by PROs is an important consideration. Bosutinib is a SRC/ABL tyrosine kinase inhibitor approved for Philadelphia chromosome-positive CML treatment in adults resistant or intolerant to prior therapy. In the BFORE trial (NCT02130557) of bosutinib versus imatinib a significantly higher major molecular response rate at 12 months (the primary endpoint) occurred with bosutinib. Here we report initial PRO results from BFORE.

Published
2017
Full Text
View/download PDF

11. Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1Transcript Level

Author

Hochhaus, Andreas, Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Iryna, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp D., García Gutiérrez, Valentín, Reilly, Laurence, Jeynes-Ellis, Allison, Crescenzo, Rocco J., Leip, Eric, Bardy-Bouxin, Nathalie, Brümmendorf, Timothy H., and Cortes, Jorge E.

Abstract

Introduction:Bosutinib is a potent SRC/ABL tyrosine kinase inhibitor approved for treatment of Philadelphia chromosome-positive CML in adults resistant or intolerant to prior therapy. This analysis evaluated the efficacy of first-line bosutinib versus imatinib in the BFORE study (NCT02130557) by 3-month BCR-ABL1transcripts ≤10% versus >10% and examined baseline and on-treatment characteristics as predictors of time to major molecular response (MMR).

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results